Abingdon Health Plc (ABDX.L)

GBp 7.75

(0.0%)

Market Cap (In GBp)

15 Million

Revenue (In GBp)

6.13 Million

Net Income (In GBp)

-1.27 Million

Avg. Volume

135.67 Thousand

Currency
GBp
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
6.5-13.0
PE
-
EPS
-
Beta Value
0.211
ISIN
GB00BLF79J41
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Mr. Chris Henry Francis Yates
Employee Count
-
Website
https://www.abingdonhealth.com
Ipo Date
2020-12-15
Details
Abingdon Health Plc develops, manufactures, and distributes diagnostic devices worldwide. It offers AbC-19 Rapid Test, a COVID-19 IgG rapid antibody test; nucleic acid lateral flow immunoassays; Seralite, a rapid lateral flow test for the quantitative measurement of kappa and lambda immunoglobulin free light chains in serum; and AppDx, a customizable image capturing technology that transforms a smartphone into a self-sufficient and standalone lateral-flow reader. The company also provides lateral flow development and manufacturing services. Additionally, it provides consultancy services to businesses in the healthcare technology sector. The company has a collaboration and co-marketing agreement with Abcam plc. Abingdon Health Plc was incorporated in 2008 and is headquartered in York, the United Kingdom.

More Stocks